AZD0780
Sponsors
Astrazeneca AB, AstraZeneca AB, AstraZeneca
Conditions
Atherosclerotic Cardiovascular DiseaseAtherosclerotic cardiovascular diseaseCardiovascular DiseaseDyslipidaemiaDyslipidemiaDyslipidemia
Dyslipidemias are alterations to the plasma lipid profile associated often with clinical condition. A common form of dyslipidemia is Hypercholesterolemia due to high level of LDL-cholesterolHealthy ParticipantsHepatic Impairment
Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
CompletedNCT05384262
Start: 2022-05-18End: 2024-06-14Updated: 2026-09-09
A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin.
CompletedNCT05787002
Start: 2023-03-09End: 2023-05-15Updated: 2025-04-27
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
CompletedNCT06576765
Start: 2024-08-08End: 2024-11-08Updated: 2025-02-10
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
CompletedNCT06592482
Start: 2024-08-02End: 2024-12-01Updated: 2025-02-20
An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
CompletedNCT06671405
Start: 2024-09-25End: 2025-02-17Updated: 2025-04-27
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
CompletedNCT06742853
Start: 2024-12-20End: 2025-10-29Updated: 2025-11-07
A Study to Investigate the Effect of AZD0780 on Metformin Pharmacokinetics in Healthy Adult Volunteers Aged 18 to 55 Years
CompletedNCT07216131
Start: 2025-11-10End: 2025-12-30Updated: 2026-01-09
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels
CompletedNCT07423598
Start: 2026-02-24End: 2026-06-29Updated: 2026-07-07
Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
CompletedNCT06173570
Start: 2024-01-19End: 2024-09-30Updated: 2025-11-17
A Phase IIb, Multicenter, Randomized, Parallel-group, Double- blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants with Dyslipidemia
CompletedCTIS2023-506197-12-00
Start: 2024-02-07End: 2024-09-25Target: 209Updated: 2024-04-12
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
CompletedNCT06692764
Start: 2024-10-30End: 2025-05-02Updated: 2026-02-18
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
Active, not recruitingNCT06834932
Start: 2024-12-06End: 2027-02-22Updated: 2026-08-26
A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia
Active, not recruitingNCT07218900
Start: 2025-11-13End: 2026-09-30Updated: 2026-09-01
Phase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
RecruitingNCT07000357
Start: 2025-06-04End: 2029-10-26Target: 15100Updated: 2026-08-24
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
Active, not recruitingNCT07000123
Start: 2025-05-28End: 2027-01-11Updated: 2026-08-11
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
Active, not recruitingNCT07000136
Start: 2025-06-10End: 2027-01-04Updated: 2026-07-16
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia
Active, not recruitingCTIS2025-520520-17-00
Start: 2025-09-05Target: 152Updated: 2025-12-12
A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Elevated Low-Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event
Active, not recruitingCTIS2025-520521-21-00
Start: 2025-09-02Target: 780Updated: 2026-01-15
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event
RecruitingCTIS2025-520519-14-00
Start: 2025-09-03Target: 3531Updated: 2026-01-19